The AKT inhibitor was used to knockdown the AKT gene in the NPC cells, and using immunohistochemical analyses of tumor xenografts previous studies have identified that repeated doses of GSK690693 reduce the number of pAKT substrates in vivo(16). This evidence concerns the gene AKT1 and neoplasm.